Table 1.
Patient characteristics
| Patient characteristics | N = 37 |
|---|---|
| Age, median (range) | 54 (24–70) |
| ≥55 years | 17 (46%) |
| ≥60 years | 15 (41%) |
| Male | 20 (54%) |
| Female | 17 (46%) |
| BM blast % prior to treatment, median (range) | 28% (6%–94%) |
| Refractory AMLa | 16 (43%) |
| Relapsed AML | 21 (57%) |
| CR duration ≤6 months | 9/21 (43%) |
| CR duration ≤1 year | 16/21 (76%) |
| Salvage therapy 1 | 28 (76%) |
| Salvage therapy 2 | 8 (22%) |
| Salvage therapy 3 | 1 (3%) |
| Secondary AML | 13 (35%) |
| ELN risk | |
| Favorable | 7 (19%) |
| Intermediate | 9 (24%) |
| Adverse | 21 (56%) |
| Genomic classificationb | |
| AML with NPM1 mutation | 9 (24%) |
| AML with mutated chromatin, RNA-splicing genes, or both | 8 (22%) |
| AML with MLL fusion genes | 8 (22%) |
| AML with TP53 mutations, chromosomal aneuploidy, or both | 6 (16%) |
| AML with Inv(3); GATA2, MECOM | 4 (11%) |
| AML with Inv(16); CBFB–MYH11 | 1 (3%) |
| AML with t(6;9); DEK–NUP214 | 1 (3%) |
| Most common mutations | |
| NPM1 | 9 (24%) |
| DNMT3A | 8 (22%) |
| ASXL1 | 6 (16%) |
| IDH2 | 6 (16%) |
| TP53 | 5 (14%) |
| CEBPA | 4 (11%) |
| NRAS | 4 (11%) |
| WT1 | 4 (11%) |
| Site | |
| University of North Carolina | 30 (81%) |
| Johns Hopkins | 7 (19%) |
Abbreviations: BM, bone marrow; ELN, European LeukemiaNet.
aRefractory AML defined as no response to one or two cycles of induction chemotherapy (>28 days after induction chemotherapy) or no response to salvage treatment after subsequent relapse.
bGenomic classification determined by Papaemmanuil et al. (19).